The mutation T477A in HIV-1 reverse transcriptase (RT) restores normal proteolytic processing of RT in virus with Gag-Pol mutated in the p51-RNH cleavage site

Retrovirology

Volumn 7, Issue , 2010, Pages

  Abram, Michael E ^a   Sarafianos, Stefan G ^b   Parniak, Michael A ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b University of Missouri   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; RIBONUCLEASE H; RNA DIRECTED DNA POLYMERASE; REVERSE TRANSCRIPTASE, HUMAN IMMUNODEFICIENCY VIRUS 1;

ARTICLE; CELL LINE; CELL STRAIN HEK293; CONTROLLED STUDY; ENZYME DEGRADATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR CLONING; MUTAGENESIS; NONHUMAN; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN PROCESSING; VIRUS MUTANT; VIRUS MUTATION; VIRUS RECOMBINANT; WILD TYPE; ANIMAL; CERCOPITHECUS; CHEMICAL STRUCTURE; GENE EXPRESSION; GENE REPRESSION; GENETICS; METABOLISM; MISSENSE MUTATION; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; VIRUS CULTURE; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANIMALS; CELL LINE; CERCOPITHECUS AETHIOPS; FUSION PROTEINS, GAG-POL; GENE EXPRESSION; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MODELS, MOLECULAR; MUTATION, MISSENSE; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, TERTIARY; SERIAL PASSAGE; SUPPRESSION, GENETIC; VIRUS REPLICATION;

EID: 77649118973     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-7-6     Document Type: Article

References (43)

1. Tisdale M, Ertl P, Larder BA, Purifoy DJ, Darby G, Powell KL. Characterization of human immunodeficiency virus type 1 reverse transcriptase by using monoclonal antibodies: role of the C terminus in antibody reactivity and enzyme function. J Virol 1988, 62(10):3662-7. 253508, 2458486.
2. Chattopadhyay D, Evans DB, Deibel MR, et al. Purification and characterization of heterodimeric human immunodeficiency virus type 1 (HIV-1) reverse transcriptase produced by in vitro processing of p66 with recombinant HIV-1 protease. J Biol Chem 1992, 267(20):14227-32.
3. Fan N, Rank KB, Leone JW, et al. The differential processing of homodimers of reverse transcriptases from human immunodeficiency viruses type 1 and 2 is a consequence of the distinct specificities of the viral proteases. J Biol Chem 1995, 270(22):13573-9.
4. Hostomska Z, Matthews DA, Davies JF, Nodes BR, Hostomsky Z. Proteolytic release and crystallization of the RNase H domain of human immunodeficiency virus type 1 reverse transcriptase. J Biol Chem 1991, 266(22):14697-702.
5. Tomasselli AG, Sarcich JL, Barrett LJ, Reardon IM, Howe WJ, Evans DB, Sharma SK, Heinrikson RL. Human immunodeficiency virus type-1 reverse transcriptase and ribonuclease H as substrates of the viral protease. Protein Sci 1993, 2(12):2167-76. 10.1002/pro.5560021216, 2142316, 7507754.
6. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992, 256(5065):1783-90. 10.1126/science.1377403, 1377403.
7. Wang J, Smerdon SJ, Jager J, Kohlstaedt LA, Rice PA, Friedman JM, Steitz TA. Structural basis of asymmetry in the human immunodeficiency virus type 1 reverse transcriptase heterodimer. Proc Natl Acad Sci USA 1994, 91(15):7242-6. 10.1073/pnas.91.15.7242, 44375, 7518928.
8. Jacobo-Molina A, Arnold E. HIV reverse transcriptase structure-function relationships. Biochemistry 1991, 30(26):6351-6. 10.1021/bi00240a001, 1711368.
9. Prasad VR, Goff SP. Structure-function studies of HIV reverse transcriptase. Ann N Y Acad Sci 1990, 616:11-21. 10.1111/j.1749-6632.1990.tb17823.x, 1706569.
10. Goff SP, Prasad VR. Linker insertion mutagenesis as probe of structure-function relationships. Methods Enzymol 1991, 208:586-603. full_text, 1723477.
11. Mizrahi V, Brooksbank RL, Nkabinde NC. Mutagenesis of the conserved aspartic acid 443, glutamic acid 478, asparagine 494, and aspartic acid 498 residues in the ribonuclease H domain of p66/p51 human immunodeficiency virus type I reverse transcriptase. Expression and biochemical analysis. J Biol Chem 1994, 269(30):19245-9.
12. Prasad VR, Goff SP. Linker insertion mutagenesis of the human immunodeficiency virus reverse transcriptase expressed in bacteria: definition of the minimal polymerase domain. Proc Natl Acad Sci USA 1989, 86(9):3104-8. 10.1073/pnas.86.9.3104, 287073, 2470090.
13. Hizi A, Hughes SH, Shaharabany M. Mutational analysis of the ribonuclease H activity of human immunodeficiency virus 1 reverse transcriptase. Virology 1990, 175(2):575-80. 10.1016/0042-6822(90)90444-V, 1691564.
14. Mizrahi V, Lazarus GM, Miles LM, Meyers CA, Debouck C. Recombinant HIV-1 reverse transcriptase: purification, primary structure, and polymerase/ribonuclease H activities. Arch Biochem Biophys 1989, 273(2):347-58. 10.1016/0003-9861(89)90493-1, 2476069.
15. Tisdale M, Schulze T, Larder BA, Moelling K. Mutations within the RNase H domain of human immunodeficiency virus type 1 reverse transcriptase abolish virus infectivity. J Gen Virol 1991, 72(1):59-66. 10.1099/0022-1317-72-1-59, 1703563.
16. Hizi A, Barber A, Hughes SH. Effects of small insertions on the RNA-dependent DNA polymerase activity of HIV-1 reverse transcriptase. Virology 1989, 170(1):326-9. 10.1016/0042-6822(89)90389-9, 2470195.
17. Starnes MC, Gao WY, Ting RY, Cheng YC. Enzyme activity gel analysis of human immunodeficiency virus reverse transcriptase. J Biol Chem 1988, 263(11):5132-4.
18. Wu J, Amandoron E, Li X, Wainberg MA, Parniak MA. Monoclonal antibody-mediated inhibition of HIV-1 reverse transcriptase polymerase activity. Interaction with a possible deoxynucleoside triphosphate binding domain. J Biol Chem 1993, 268(14):9980-5.
19. Fletcher RS, Holleschak G, Nagy E, Arion D, Borkow G, Gu Z, Wainberg MA, Parniak MA. Single-step purification of recombinant wild-type and mutant HIV-1 reverse transcriptase. Protein Expr Purif 1996, 7(1):27-32. 10.1006/prep.1996.0004, 9172779.
20. Bathurst IC, Moen LK, Lujan MA, Gibson HL, Feucht PH, Pichuantes S, Craik CS, Santi DV, Barr PJ. Characterization of the human immunodeficiency virus type-1 reverse transcriptase enzyme produced in yeast. Biochem Biophys Res Commun 1990, 171(2):589-95. 10.1016/0006-291X(90)91187-W, 1698361.
21. Hansen J, Schulze T, Mellert W, Moelling K. Identification and characterization of HIV-specific RNase H by monoclonal antibody. EMBO J 1988, 7(1):239-43. 454263, 2452083.
22. Abram ME, Parniak MA. Virion instability of human immunodeficiency virus type I reverse transcriptase (RT) mutated in the protease cleavage site between RT p51 and the RT RNase H domain. J Virol 2005, 79(18):11952-61. 10.1128/JVI.79.18.11952-11961.2005, 1212597, 16140771.
23. Pettit SC, Everitt LE, Choudhury S, Dunn BM, Kaplan AH. Initial Cleavage of the Human Immunodeficiency Virus Type 1 GagPol Precursor by Its Activated Protease Occurs by an Intramolecular Mechanism. J Virol 2004, 78(16):8477-85. 10.1128/JVI.78.16.8477-8485.2004, 479095, 15280456.
24. Pettit SC, Sheng N, Tritch R, Erickson-Viitanen S, Swanstrom R. The regulation of sequential processing of HIV-1 Gag by the viral protease. Adv Exp Med Biol 1998, 436:15-25.
25. Speck RR, Flexner C, Tian CJ, Yu XF. Comparison of human immunodeficiency virus type 1 Pr55(Gag) and Pr160(Gag-pol) processing intermediates that accumulate in primary and transformed cells treated with peptidic and nonpeptidic protease inhibitors. Antimicrob Agents Chemother 2000, 44(5):1397-403. 10.1128/AAC.44.5.1397-1403.2000, 89883, 10770790.
26. Lindhofer H, von der HK, Nitschko H. In vivo processing of Pr160gag-pol from human immunodeficiency virus type 1 (HIV) in acutely infected, cultured human T-lymphocytes. Virology 1995, 214(2):624-7. 10.1006/viro.1995.0074, 8553565.
27. Wiegers K, Rutter G, Kottler H, Tessmer U, Hohenberg H, Krausslich HG. Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites. J Virol 1998, 72(4):2846-54. 109729, 9525604.
28. Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, Shafer RW. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 2003, 31(1):298-303. 10.1093/nar/gkg100, 165547, 12520007.
29. Navarro JM, Damier L, Boretto J, Priet S, Canard B, Quérat G, Sire J. Glutamic Residue 438 within the Protease-Sensitive Subdomain of HIV-1 Reverse Transcriptase Is Critical for Heterodimer Processing in Viral Particles. Virology 2001, 290(2):300-8. 10.1006/viro.2001.1188, 11883194.
30. Graves MC, Meidel MC, Pan YC, Manneberg M, Lahm HW, Gruninger-Leitch F. Identification of a human immunodeficiency virus-1 protease cleavage site within the 66,000 Dalton subunit of reverse transcriptase. Biochem Biophys Res Commun 1990, 168(1):30-6. 10.1016/0006-291X(90)91670-N, 1691640.
31. Ren J, Milton J, Weaver KL, Short SA, Stuart DI, Stammers DK. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. Structure 2000, 8(10):1089-94. 10.1016/S0969-2126(00)00513-X, 11080630.
32. Chiang C-C, Wang S-M, Tseng Y-T, Huang K-J, Wang C-T. Mutations at human immunodeficiency virus type 1 reverse transcriptase tryptophan repeat motif attenuate the inhibitory effect of efavirenz on virus production. Virology 2009, 383(2):261-270. 10.1016/j.virol.2008.10.027, 19019404.
33. Tachedjian G, Orlova M, Sarafianos SG, Arnold E, Goff SP. Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase. Proc Natl Acad Sci USA 2001, 98(13):7188-7193. 10.1073/pnas.121055998, 34644, 11416202.
34. Le Grice SF, Mills J, Mous J. Active site mutagenesis of the AIDS virus protease and its alleviation by trans complementation. EMBO J 1988, 7(8):2547-53. 457126, 2461297.
35. Mous J, Heimer EP, Le Grice SF. Processing protease and reverse transcriptase from human immunodeficiency virus type I polyprotein in Escherichia coli. J Virol 1988, 62(4):1433-6. 253157, 2450209.
36. Li X, Amandoron E, Wainberg MA, Parniak MA. Generation and characterization of murine monoclonal antibodies reactive against N-terminal and other regions of HIV-1 reverse transcriptase. J Med Virol 1993, 39(3):251-9. 10.1002/jmv.1890390314, 7682257.
37. Munk C, Brandt SM, Lucero G, Landau NR. A dominant block to HIV-1 replication at reverse transcription in simian cells. Proc Natl Acad Sci USA 2002, 99(21):13843-8. 10.1073/pnas.212400099, 129785, 12368468.
38. Fisher AG, Collalti E, Ratner L, Gallo RC, Wong-Staal F. A molecular clone of HTLV-III with biological activity. Nature 1985, 316(6025):262-5. 10.1038/316262a0, 2410792.
39. Borkow G, Fletcher RS, Barnard J, Arion D, Motakis D, Dmitrienko GI, Parniak MA. Inhibition of the ribonuclease H and DNA polymerase activities of HIV-1 reverse transcriptase by N-(4-tert-butylbenzoyl)-2-hydroxy-1- naphthaldehyde hydrazone. Biochemistry 1997, 36(11):3179-85. 10.1021/bi9624696, 9115994.
40. Motakis D, Parniak MA. A tight-binding mode of inhibition is essential for anti-human immunodeficiency virus type 1 virucidal activity of nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002, 46(6):1851-6. 10.1128/AAC.46.6.1851-1856.2002, 127238, 12019100.
41. Johnson VA, Byington RE. Techniques in HIV research 1990, 71-6. New York, N.Y.: Stockton Press, Aldovini A, Walker BD.
42. Hsiou Y, Ding J, Das K, Clark AD, Hughes SH, Arnold E. Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms. Structure 1996, 4(7):853-60. 10.1016/S0969-2126(96)00091-3, 8805568.
43. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem 2004, 25(13):1605-12. 10.1002/jcc.20084, 15264254.